P-1431. Electronic Nudges to Increase Influenza Vaccination in Immunocompromised Individuals: a secondary analysis of the NUDGE-FLU-CHRONIC trial
Abstract
Abstract Background Immunosuppressed individuals are at higher risk for influenza-related complications, yet vaccination rates remain low, particularly among young and middle-aged adults. This secondary analysis of the NUDGE-FLU-CHRONIC trial assessed the impact of letter-based nudges on influenza vaccine uptake by immunosuppression status.Table 1: Baseline Characteristics by Immunosuppression StatusTable 2: Baseline Characteristics by Randomization to Any Letter or Usual Care in Participants with Immunosuppression Methods All Danish citizens aged 18–64 with chronic conditions eligible for free influenza vaccination during the 2023/24 season were enrolled. Participants were randomly assigned to no letter (usual care), or one of six electronic nudges delivered via the national governmental electronic letter system. All data were obtained from national registries. Immunosuppression was defined as a diagnosis of HIV, congenital immunodeficiency, or transplantation ≤10 years before randomization, or ≥1 filled prescription for an immunosuppressant or systemic glucocorticoid ≤180 days before randomization. The primary endpoint was influenza vaccination by January 1, 2024. Vaccination rates were compared using χ² tests and presented as absolute differences in proportions. Effect modification by immunosuppression status was assessed using binomial regression models with interaction terms.Figure 1: Vaccination rates by immunosuppression status Bar chart with 95% confidence intervals…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 299,881 participants or records.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.